Our story

CuraVac was founded in 2002 by Dr. Stéphane Huberty, a Belgian medical doctor who suffered from myasthenia gravis (MG). Soon after, the company acquired the complementary peptide patent, raised funds and got organized as a management company at the center of a network of collaborations and sub-contracting companies. The original discoverer of the Targeted Active immunotherapy technology, Professor J. Edwin Blalock also joined CuraVac as a consultant.

In 2002, the company was created and acquired the complementary peptide patent. The company raised funds and got organized as a management company in the center of an expertise and competence network of collaborations and sub-contracting companies.

In 2006, the key article showing that the MG vaccine works not only in the lab on rat models but also on naturally occurring myasthenia gravis in pet dogs is published and the MG vaccine patent is filed.

In 2007, Nicolas Havelange joined CuraVac and together, he and Dr. Huberty have taken this Active Targeted Immunotherapy technology production technique out of the lab to bring it to patients.

In 2009, the human formulation of the MG vaccine is manufactured following GLP and GMP guidelines.
The myasthenia gravis Targeted Active Therapy, our therapys, was granted Orphan Drug Designation in Europe by a team of independent experts of the 27 European member states.

In 2011, the MG therapeutic vaccine was granted Orphan Drug Designation in the USA by the FDA

In 2013, following a call for proposals that was answered by all the best medicine projects in the world, CuraVac’s project for a MG Targeted Active Therapy was one of the 7 therapeutic vaccine-like projects that were selected by an Independent Jury Committee of the best world experts.
CuraVac then created a European consortium of four companies and one University Medical Center that received the support of the FP7 2013 Health Innovation to conduct clinical trials of the MG Targeted Active Therapy: MYASTERIX.

Following a Clinical Trial Authorization received in November 2015, 24 patients received three injections of the MG Targeted Active Therapy in a phase 1B clinical trial that took place at the Antwerp University hospital (UZA) in Belgium. The preliminary results were communicated in May 2017 at the 13th International Conference on Myasthenia Gravis and Related Disorders at the New York Academy of Science.

The final results of phase 1B, communicated in June 2018, demonstrated an excellent safety profile, and called for a phase 2 efficacy clinical trial with a more potent formulation of the MG Targeted Active Therapy: CV-MG02.